A project harnessing modified immune cells to target cancers will see Sydney leading innovative cancer therapies.
The University of Sydney and Children’s Medical Research Institute (CMRI) have announced the execution of an agreement with biopharmaceutical company, Biosceptre (BCIQ), to establish a new research program on CAR-T cell immunotherapy, at Westmead, Western Sydney.
To read more about this remarkable research, and Dr Patrick Schlegel, the German paediatric oncologist, and leader in CAR-T technology, who will be leading the Sydney research team, press the link below